Protalix Accounts Payable from 2010 to 2026

PLX Stock  USD 2.97  0.11  3.85%   
Protalix Biotherapeutics Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable will likely drop to about 4.1 M in 2026. Accounts Payable is the amount Protalix Biotherapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Protalix Biotherapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
1998-12-31
Previous Quarter
6.7 M
Current Value
5.4 M
Quarterly Volatility
M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 49.3 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.79, Dividend Yield of 0.0 or PTB Ratio of 3.45. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Protalix Stock
Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
The evolution of Accounts Payable for Protalix Biotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Protalix Biotherapeutics compares to historical norms and industry peers.

Latest Protalix Biotherapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Protalix Biotherapeutics over the last few years. An accounting item on the balance sheet that represents Protalix Biotherapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Protalix Biotherapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Protalix Biotherapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Very volatile
   Accounts Payable   
       Timeline  

Protalix Accounts Payable Regression Statistics

Arithmetic Mean5,442,138
Geometric Mean4,632,934
Coefficient Of Variation45.86
Mean Deviation1,647,549
Median5,212,950
Standard Deviation2,495,661
Sample Variance6.2T
Range12.2M
R-Value(0.03)
Mean Square Error6.6T
R-Squared0
Significance0.90
Slope(16,957)
Total Sum of Squares99.7T

Protalix Accounts Payable History

20264.1 M
20255.2 M
20244.5 M
20234.3 M
20225.9 M
2021M
20207.2 M

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable5.2 M4.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.